Beam Therapeutics (BEAM) News Today $17.41 +0.41 (+2.39%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by Alliancebernstein L.P.Alliancebernstein L.P. grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 149.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,804 shares of the company's stock after purchApril 15 at 3:57 AM | marketbeat.comJPMorgan Chase & Co. Trims Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)JPMorgan Chase & Co. lessened its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 19.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 513,671 shares of the company's stock after selling 125,567 shares during theApril 15 at 3:22 AM | marketbeat.comAIIMS-Bathinda eyes CSR funds to set up proton beam therapy for cancer treatmentApril 14 at 10:43 PM | msn.comNorges Bank Buys Shares of 18,591 Beam Therapeutics Inc. (NASDAQ:BEAM)Norges Bank purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 18,591 shares of the company's stock, valued at approximately $461,000. AApril 14 at 3:29 AM | marketbeat.comBeam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measuresApril 11, 2025 | finance.yahoo.comCathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics todayApril 11, 2025 | markets.businessinsider.comBeam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?April 10, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Reaches New 52-Week Low - Here's WhyBeam Therapeutics (NASDAQ:BEAM) Sets New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM)HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a report on Monday.April 9, 2025 | marketbeat.comBeam Therapeutics (BEAM) Gets a Buy from ScotiabankApril 8, 2025 | markets.businessinsider.comVanguard Group Inc. Lowers Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)Vanguard Group Inc. trimmed its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,621,989 shares of the company's stock after seApril 8, 2025 | marketbeat.comRaymond James Financial Inc. Takes $703,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Raymond James Financial Inc. bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 28,328 shares of the company's stock, valued at approximately $703,00April 7, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives $49.45 Average PT from AnalystsApril 7, 2025 | americanbankingnews.comBeam Therapeutics presents additional data for BEAM-302 in AATDApril 6, 2025 | markets.businessinsider.comCinctive Capital Management LP Invests $1.62 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Cinctive Capital Management LP bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 65,242 shares of the company's stock,April 6, 2025 | marketbeat.comInsider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells 5,674 Shares of StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 5,674 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $104,117.90. Following the sale, the insider now owns 117,294 shares in the company, valued at approximately $2,152,344.90. This represents a 4.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.April 5, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) President Sells $136,413.90 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 7,434 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $136,413.90. Following the completion of the sale, the president now directly owns 190,216 shares in the company, valued at approximately $3,490,463.60. This represents a 3.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.April 5, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $562,666.05 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 30,663 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $562,666.05. Following the sale, the chief executive officer now owns 986,249 shares in the company, valued at $18,097,669.15. The trade was a 3.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 5, 2025 | marketbeat.comBeam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin DeficiencyApril 5, 2025 | finanznachrichten.deBeam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient CongressApril 5, 2025 | globenewswire.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Buy" by BrokeragesBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received a consensus recommendation of "Buy" from the fourteen brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strongApril 5, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Trading 3.7% Higher - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Trading Up 3.7% - Should You Buy?April 4, 2025 | marketbeat.comShort Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Grows By 21.7%Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 12,160,000 shares, a growth of 21.7% from the February 28th total of 9,990,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is currently 7.7 days. Currently, 15.3% of the company's stock are sold short.April 4, 2025 | marketbeat.comChristine Bellon Sells 5,674 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockApril 4, 2025 | insidertrades.comIs Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?April 3, 2025 | finance.yahoo.comIs Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?April 2, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Sets New 52-Week Low - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Sets New 52-Week Low - Time to Sell?April 2, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 10.6% - Time to Sell?Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 10.6% - Time to Sell?April 1, 2025 | marketbeat.comThe Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR TherapeuticsMarch 31, 2025 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Raised to Buy at Bank of AmericaBank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price on the stock in a research note on Friday.March 29, 2025 | marketbeat.comIQ EQ FUND MANAGEMENT IRELAND Ltd Has $799,000 Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 145.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,198 shares of the company's stock after buying an additional 19,080 sharesMarch 29, 2025 | marketbeat.comBeam Therapeutics upgraded to Buy at BofA after BEAM-302 dataMarch 28, 2025 | markets.businessinsider.comBeam Therapeutics upgraded to Buy from Neutral at BofAMarch 28, 2025 | markets.businessinsider.comB of A Securities Upgrades Beam Therapeutics (BEAM)March 28, 2025 | msn.comBeam announces FDA clearance of BEAM-302 investigational new drug applicationMarch 28, 2025 | markets.businessinsider.comBeyond The Numbers: 9 Analysts Discuss Beam Therapeutics StockMarch 28, 2025 | benzinga.comBIT Capital GmbH Invests $878,000 in Beam Therapeutics Inc. (NASDAQ:BEAM)BIT Capital GmbH bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 35,414 shares of the company's stock, valued at approximateMarch 28, 2025 | marketbeat.comBeam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?March 27, 2025 | msn.comBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug AdministrationMarch 27, 2025 | globenewswire.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 3.8% - Time to Sell?Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 3.8% - What's Next?March 26, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics todayMarch 26, 2025 | markets.businessinsider.comCathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stockMarch 25, 2025 | investing.comProficio Capital Partners LLC Buys Shares of 16,368 Beam Therapeutics Inc. (NASDAQ:BEAM)Proficio Capital Partners LLC purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 16,368 shares of the company's stock, valued at approximately $4March 25, 2025 | marketbeat.comYiheng Capital Management L.P. Sells 337,658 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Yiheng Capital Management L.P. decreased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,102 shares of theMarch 22, 2025 | marketbeat.comUpgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene TherapyMarch 22, 2025 | seekingalpha.comQ1 EPS Estimate for Beam Therapeutics Increased by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company willMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $16.09 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Charles Schwab Investment Management Inc. lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 3.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 648,945 shares of the company's stock after buying anMarch 21, 2025 | marketbeat.comAlphaQuest LLC Reduces Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)AlphaQuest LLC trimmed its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 92.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,610 shares of the company's stock after selling 33,583 shares duringMarch 20, 2025 | marketbeat.comNikko Asset Management Americas Inc. Purchases 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Nikko Asset Management Americas Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 11.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,957,611 shares of the company's stock aMarch 18, 2025 | marketbeat.comIs Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?March 16, 2025 | insidermonkey.com Remove Ads Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.640.80▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼127▲BEAM Articles Average Week Remove Ads Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News BBIO News TGTX News LEGN News TLX News SRPT News BPMC News AXSM News NUVL News ADMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAM Stock Free BEAM Stock Alerts